-Politico Report
PDS Biotech To Present Updated Data At 2023 American Society Of Clinical Oncology Annual Meeting Highlighting Combination Of PDS0101 And KEYTRUDA In Head And Neck Cancer Patients
PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced the presentation of updated data